Clinical Conversations: SACP: The Skinny on the GLP-1 Agonists (Part 1)
Recent trends indicate the GLP-1 market will exceed $100 billion by 2030; this is not a surprise for the health care system as discussion and use of these medications within this class has continued to soar. As the prescribing of these medications continue to increase, pharmacists in all settings must be well versed to ensure they are able to provide appropriate counseling, education, and adjustments for patients and provide clinical insight to the healthcare team.
The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.